TOLNAFTATE’S REMARKABLE TRANSFORMATION

Introduction to Tolnaftate
Tolnaftate, synthesized in the early 1960s by Japanese scientists, was classified as a Category 1 GRASE drug (Generally Recognized As Safe and Effective) by the U.S. FDA in 1965. The FDA issued the Final Monograph for tolnaftate on September 23, 1994, after confirming its safety with minimal adverse reactions like intense itching and skin irritation.
Solubility and Early Limitations
Initially, tolnaftate's insolubility in water and oil limited its effectiveness in suspensions, despite its broad in vitro activity against various fungi, including Epidermophyton, Microsporum, Trichophyton species, and Malassezia furfur. Tolnaftate inhibits squalene epoxidase, impacting fungal growth and biosynthesis.
Administration and Pharmacokinetics
Tolnaftate is ineffective when administered orally or parenterally, so it is only used topically. Studies show no systemic metabolism or percutaneous absorption. High doses in animals (14 g/kg orally in dogs) showed no toxicity, and topical application in rabbits did not cause sensitization or irritation. Human studies indicated negligible toxicity, even with extensive body application.
FDA Monograph and Regulations
The monograph system simplifies product manufacturing with tolnaftate, eliminating the need for pre-approval if guidelines are followed. The monograph details precise labeling requirements, including the mandatory statement: “This product is not effective on scalp or nails.” Deviating from approved formulations or combining tolnaftate with unapproved substances like colloidal silver or DMSO necessitates a New Drug Application (NDA).
Breakthrough with Soluble Tolnaftate
The Tetra Corporation revolutionized tolnaftate application by developing Soluble Tolnaftate, with particles less than 1 nm in size. This form is indefinitely stable in jojoba oil and penetrates skin and nails effectively, unlike suspensions that leave residue on the surface.
Solution vs. Colloid
  • Solution: Particles (0.1-1 nm) are not affected by gravity, ensuring stability and effective absorption without filtration.

  • Colloid: Particles are slightly affected by gravity and may separate over time. They are filterable if larger than 25 nm.
  • Solution = .1 to 1nm
    In a Solution – Particles of Tolnaftate are not affected by gravity – Soluble Tolnaftate (solute) will not settle. (indefinitely stable) Tyndall Effect is the scattering of light by particles in a mixture. Solutions allow light to pass through. In a solution, the solute (tolnaftate) takes on the properties of the solvent (jojoba oil) = Soluble Tolnaftate.16 The smallest commercial filter available today is 25 nanometers. No filter available today can filter solutions. Solutions, therefore, are not filterable and by all standards, are the optimal delivery form for Active Pharmaceutical Ingredients.
    Colloids = 1 to 1000nm
    In Colloids – Particles are slightly affected by gravity. Brownian Motion (states that the random erratic movement of the solvent colliding with the solute particles keeps the solute from settling. They separate slowly on standing. (60 years (1 nanometer) to 2 days (1 Micron) – this is determined by particle size) Colloids are filterable if they are larger than 25 nanometers. Also, filterable by semi-permeable membranes found in the cell walls of all living organisms.
    Suspension= >1000nm
    In a Suspension – Particles are affected by gravity and will settle out in 30 minutes to 48 Hours. Tyndall Effect is the scattering of light by particles in a mixture. Suspensions DO NOT allow light to pass through. In a suspension, the solute DOES NOT take on the properties of the solvent. Suspensions are filterable. Also, filterable by semi-permeable membranes found in the cell walls of all living organisms.

    Gold Standard in Tolnaftate Delivery

    Soluble Tolnaftate is the industry standard for effective delivery to infection sites. The Tetra Corporation, leading in tolnaftate technology since 1989, maintains exclusive, proprietary processes. Their products, including Formula 7® and FungiFoam®, ensure optimal penetration and efficacy.

    Scientific References for Tolnaftate

    T. Noguchi, A. Kaji, Y. Igarashi, A. Shigematsu, and K. Taniguchi. Antitrichophyton activity of naphthiomates. Antimicrobial Agents and Chemotherapy, 1963, pp. 259-267.

    CFR Title 21, Chapter I, Subchapter D, Part 333. Topical Antimicrobial Drug Products for Over-the-Counter Human Use. Section 333.210 – Antifungal Active Ingredients.

    H. M. Robinson Jr. Antimicrobial Agents and Chemotherapy, 1964, Vol. 4, p. 608.

    The Merck Index, 11th Edition. Edited by S. Budavari, Merck and Co., Inc., Rahway, N.J., USA, 1989, p. 1499.

    H. M. Robinson Jr. and J. Raskin. Journal of Investigative Dermatology, 1964, Vol. 12, p. 185.

    L. Goldman and A. E. Lasser. Antimicrobial Agents and Chemotherapy, 1964, Vol. 4, p. 602.

    The Merck Index, 12th Edition. Entry #9656.

    Martindale: The Extra Pharmacopoeia, 31st Edition. Edited by J. E. F. Reynolds, Royal Pharmaceutical Society, London, UK, 1996, p. 416.

    Barrett-Bee, K., and Dixon, G. Ergosterol biosynthesis inhibition: A target for antifungal agents. Acta Biochimica Polonica, 1995, Vol. 42(4), pp. 465-479.

    Georgopapadakou, N. H., and Bertasso, A. Effects of squalene epoxidase inhibitors on Candida albicans. Antimicrobial Agents and Chemotherapy, 1992, Vol. 36(8), pp. 1779-1781.

    Favre, B., and Ryder, N. S. Characterization of squalene epoxidase activity from the dermatophyte Trichophyton rubrum and its inhibition by terbinafine and other antimycotic agents. Antimicrobial Agents and Chemotherapy, 1996, Vol. 40(2), pp. 443-447.

    Favre, B., et al. Comparison of in vitro activities of 17 antifungal drugs against a panel of 20 dermatophytes using a microdilution assay. Journal of Clinical Microbiology, 2003, Vol. 41(10), pp. 4817-4819.

    Kobayashi, Y., et al. Enhancing effect of N-acetyl-L-cysteine or 2-mercaptoethanol on the in vitro permeation of 5-fluorouracil or tolnaftate through the human nail plate. Chemical and Pharmaceutical Bulletin (Tokyo), 1998, Vol. 46(11), pp. 1797-1802.

    Oh, K., et al. Effects of antimycotics on the biosynthesis of cellular macromolecules in Aspergillus niger protoplasts. Mycopathologia, 1993, Vol. 122(3), pp. 135-141.

    S. N. Khan, K. K. Maggon, and T. A. Venkitasubramanian. Applied and Environmental Microbiology, 1978, Vol. 36, p. 270.

    The Tetra Corporation. U.S. Patent #4,810,498; U.S. Patent #RE 36,253; U.S. Patent #10,959,975.